Microbiome-Drug Interactions: A Critical Review of Pharmacokinetic and Pharmacodynamic Modulation

Abstract

The human microbiome functions as a powerful metabolic organ that affects drug pharmacokinetics and pharmacodynamics (PK/PD). While pharmaceuticals simultaneously alter microbial communities—a process known as pharmacoecology and toxicomicrobiomics—this reciprocal relationship, known as Pharmacomicrobiomics is the study of how microbial variety impacts the toxicity and effectiveness of medications. Microbes have the power to activate medications, bioaccumulate, inactivate prodrugs, and chemically alter pharmaceuticals—all of which have a significant impact on how various patients react to treatment. The microbial genes, enzymes, and pathways involved in medication biotransformation, which have been mapped by improvements in multi-omics profiling, inspire innovative therapies such as probiotics, enzyme inhibitors, dietary modifications, and fecal microbiota transplantation to optimize therapy. These tactics seek to decrease adverse medication reactions and improve treatment precision. However, there are ethical and regulatory issues in creating treatments based on the microbiota. The classification, manufacturing standards, safety, informed consent, privacy, equity, and long-term monitoring of live biotherapeutics, prebiotics, probiotics, and transplants must all be covered in their respective frameworks. Personal identification, biobanking, and the social repercussions of microbiome modification are further ethical issues. In conclusion, incorporating microbiome science into pharmacology has the potential to revolutionize precision medicine; nevertheless, strict ethical and regulatory control is necessary for its safe, equitable, and moral clinical application.